MarginsXMarginsX
Home › Markets › Health Care › EVMN

Evommune Inc. (EVMN)

EVMN trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$7.10
-6.95% on the day
Market cap
$293.6M
Micro cap
Revenue · 2025
$13.0M
+85.7% on 2024
Net income · 2025
-$68.9M
-529.8% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/2044725/000119312526093932/0001193125-26-093932-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerEVMN on NYSE
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2025
SEC CIK0002044725
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$13.0M
Net income-$68.9M
Operating income-$81.1M
Net margin-529.8%
Operating margin-623.6%
Revenue growth+85.7%
Cash$44.1M
Total assets$224.9M
P/E (computed)Net income was not positive
P/S (computed)22.6×

Warning signs

Cash runway
6.3 months
$47.6M cash at September 30, 2026
Share count, 1 year
+31.2%
2025-12-10 to 2026-11-10
Going-concern doubt
No
10-Q filed November 12, 2026
Insider net buying, 12 months
$42.9M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-12
Cash and burn$47.6M cash; operating cash flow -$22.6M a quarter.Report 2026-09-30
Shares outstanding41,349,860 (2026-11-10); 31,524,093 a year earlier.Cover page 2026-11-10
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorBDO USA, P.C., New York, New York, United StatesPCAOB Form AP 2026-03-06
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $45.2M, sold $2.3M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$0-$30.9M-$25.9M$47.6MNo debt tags$010-Q 2026-11-12
Q2 2026
2026-06-30
$0-$32.2M-$20.3M$60.0MNo debt tags$10.0M10-Q 2026-08-06
Q1 2026
2026-03-31
$0-$21.7M-$27.5M$48.3MNo debt tags$10.0M10-Q 2026-05-07
Q4 2025
2025-12-31
$0-$28.3M-$16.7M$44.1MNo debt tags$13.0M10-K 2026-03-05
Q3 2025
2025-09-30
$10.0M-$12.5M-$9.6M$26.8MNo debt tags$13.0M10-Q 2026-11-12
Q2 2025
2025-06-30
$0-$13.6M-$26.2M$61.8MNo debt tagsNeeds four quarters10-Q 2026-08-06
Q1 2025
2025-03-31
$3.0M-$14.6M-$23.9M$5.7MNo debt tagsNeeds four quarters10-Q 2026-05-07
Q4 2024
2024-12-31
$0-$20.7M-$18.5M$16.3MNo debt tags$7.0M10-K 2026-03-05

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32026-11-12
Latest annual report10-K2026-03-05
Latest quarterly / interim10-Q2026-11-12
Latest current report8-K2026-11-12
Latest proxyDEFA14A2026-04-21

Source: SEC EDGAR submissions feed, 144 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+14.7%
1 month+29.8%
3 months-45.8%
Year to date-55.4%
1 year-58.1%
From 52-week high-75.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
EBSEmergent BioSolutions Inc.$5.81+0.35%$298.7M
ALTAltimmune Inc.$1.56-5.17%$303.6M
FULCFulcrum Therapeutics Inc.$3.71-1.59%$283.4M
GALTGalectin Therapeutics Inc.$3.02-0.98%$305.2M
BNTCBenitec Biopharma Inc.$8.54-5.53%$308.5M
ENTAEnanta Pharmaceuticals Inc.$10.67-2.91%$310.8M
LRMRLarimar Therapeutics Inc.$3.00-0.66%$311.6M
PRLDPrelude Therapeutics Incorporated$3.41-1.16%$272.1M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier